Teoria dei modelli / Chen-Chung Chang e H. Jerome Keisler ; [trad. di Maurizio Negri]

• Record Nr.: UNISA990005599820203316
• Autore: CHANG, Chen-Chung
• Pubbl/distr/stampa: Torino : Boringhieri, 1980
• Descrizione fisica: 538 p. ; 24 cm
• Collana: Testi e manuali della scienza contemporanea. Serie di logica matematica / diretta da Corrado Mangione
• Altri autori (Persone): KEISLER, H. Jerome
• Disciplina: 511.34
• Soggetti: TEORIA DEI MODELLI
• Collocazione: XV.17. 102 (F.V. CHA (116)
• Lingua di pubblicazione: Italiano
• Formato: Materiale a stampa
• Livello bibliografico: Monografia
• Note generali: Traduzione di: Model theory

Description of the Fork Mountain long-term soil productivity study [[electronic resource] ] : site characterization / / Mary Beth Adams ... [and others]

• Record Nr.: UNINA9910695867103321
• Pubbl/distr/stampa: Newtown Square, PA : , : U.S. Dept. of Agriculture, Forest Service, Northeastern Research Station, , [2004]
• Descrizione fisica: 40 pages : digital, PDF file
• Collana: General technical report NE ; ; 323
• Altri autori (Persone): AdamsMary Beth <1958->
• Soggetti: Soil productivity - East (U.S.); Forest soils - Effect of logging on - East (U.S.); Hardwoods - Effect of air pollution on - East (U.S.)
• Lingua di pubblicazione: Inglese
• Formato: Materiale a stampa
• Livello bibliografico: Monografia
• Note generali: Title from title screen (viewed on Jan. 4, 2005).; "November 2004."
• Nota di bibliografia: Includes bibliographical references (pages 32-34).

Contemporary drug synthesis / / Jie Jack Li [et al.]

• Record Nr.: UNISA996211665003316
• Pubbl/distr/stampa: Hoboken, N.J. : , : Wiley-Interscience, , 2004; ©2004
• ISBN: 1-280-27291-0; 9786610272914; 0-470-23708-2; 0-471-68673-5; 0-471-68674-3
• Edizione: [1st ed.]
• Descrizione fisica: 1 online resource (xv, 221 pages) : illustrations
• Altri autori (Persone): LiJie Jack
• Disciplina: 615/.31
• Soggetti: Pharmaceutical chemistry; Drugs - Design
• Lingua di pubblicazione: Inglese
• Formato: Materiale a stampa
• Livello bibliografico: Monografia
• Note generali: Description based upon print version of record.
• Nota di bibliografia: Includes bibliographical references and index.
• Nota di contenuto: Contemporary Drug Synthesis; Preface; Table of Contents; Trade Names and Their Corresponding USANs; Acronyms and Abbreviations; Chapter 1: Antithrombotics: Ticlopidine (Ticlid® and Clopidogrel (Plavix®); 1 .1 Introduction; 1.2 Syntheses of ticlopidine; 1.3 Syntheses of clopidogrel; 1.4 References; Chapter 2. Anti-inflammatory Cyclooxygenase-2 Selective Inhibitors: Celecoxib (Celebrex®) and Rofecoxib (Vioxx®); 2.1 Introduction; 2.2 Synthesis of celecoxib; 2.3 Syntheses of rofecoxib; 2.4 References; Chapter 3. H+/K+-ATPase Inhibitors: Esomeprazole (Nexium®); 3.1 Introduction; 3.2 Synthesis of esomeprazole; 3.2.1 Separation using HPLC; 3.2.2 Asymmetric oxidation of the sulfide; 3.2.3 Biooxidation; 3.3 References; Chapter 4. Protein-tyrosine Kinase Inhibitors: Imatinib (Gleevec®) and Gefitinib (Iressa®); 4.1 Introduction to Gleevec®; 4.2 Synthesis of imatinib mesylate; 4.3 Introduction to Iressa®; 4.4 Synthesis of gefitinib; 4.5 References; Chapter 5. Non-sedating Antihistamines; 5.1 Introduction; 5.2 Synthesis of loratadine and desloratadine; 5.3 Synthesis of fexofenadine; 5.4 Synthesis of cetirizine; 5.5 References; Chapter 6. Cosmeceuticals: Isotretinoin (Accutane®), Tazarotene (Tazorac®), Minoxidil (Rogaine®), and Finasteride (Propecia®); 6.1 Isotretinoin; 6.1.1 Introduction to isotretinoin; 6.1.2 Synthesis of isotretinoin; 6.2 Tazarotene; 6.2.1 Introduction to tazarotene; 6.2.2 Synthesis of tazarotene; 6.3 Minoxidil; 6.3.1 Introduction to minoxidil; 6.3.2 Synthesis of minoxidil; 6.4 Finasteride; 6.4.1 Introduction to finasteride; 6.4.2 Synthesis of finasteride; 6.5 References; Chapter 7. Antibacterials: Ciprofloxacin (Cipro®) and Linezolid (Zyvox®); 7.1 Ciprofloxacin (Cipro®); 7.1.1 Introduction to ciprofloxacin 7.1.2 Synthesis of ciprofloxacin; 7.2 Linezolid (Zyvox®); 7.2.1 Introduction to linezolid; 7.2.2 Synthesis of linezolid; 7.3 References; Chapter 8. Atypical Antipsychotics; 8.1 Introduction; 8.2 Synthesis of risperidone; 8.3 Synthesis of olanzapine; 8.4 Synthesis of quetiapine fumarate; 8.5 Synthesis of ziprasidone; 8.6 Synthesis of aripiprazole; 8.7 References; Chapter 9. Atorvastatin Calcium (Lipitor®); 9.1 Background; 9.2 Synthesis of racemic atorvastatin; 9.3 Enantioselective syntheses of atorvastatin calcium; 9.4 References; Chapter 10. Antidepressants; 10.1 Background; 10.2 Synthesis of fluoxetine hydrochloride; 10.3 Synthesis of sertraline hydrochloride; 10.4 Synthesis of paroxetine hydrochloride; 10.5 References; Chapter 11. Anti-obesity: Orlistat (Xenical®); 11.1 Introduction; 11.2 Synthesis of orlistat; 11.3 References; Chapter 12. Triptans for Migraine; 12.1 Introduction; 12.2 Synthesis of sumatriptan; 12.3 Synthesis of zolmitriptan; 12.4 Synthesis of naratriptan; 12.5 Synthesis of rizatriptan; 12.6 Synthesis of almotriptan; 12.7 Synthesis of frovatriptan; 12.8 Synthesis of eletriptan; 12.9 References
• Sommario/riassunto: An integrated and insightful look at successful drug synthesis in today's drug discovery market The pharmaceutical industry is unquestionably vibrant today, with drug synthesis making a vital contribution. Whether in the early developmental stages of identifying and optimizing a lead, or the latter stages of process development and cost-effective scale-up, the ability to design elegant and economical synthetic routes is often a major factor in the eventual viability and commercial success of a drug.